Colorectal Cancer Screening

Colorectal cancer (CRC) is the second deadliest cancer in the US, causing over 50,000 deaths annually.¹

Learn More

Colorectal Cancer Screening

Colorectal cancer (CRC) is the second deadliest cancer in the US, causing over 50,000 deaths annually.¹ Leading organizations like the United States Preventive Service Task Force (USPSTF) and the American Cancer Society (ACS) recommend screening for average-risk individuals starting at age 45. However, millions of eligible patients often avoid screening due to unpleasant procedures or the perceived low risk of developing CRC compared to other cancers.

At Geneoscopy, our goal is to improve colorectal cancer screening with our multi-target stool RNA (mt-sRNA) biomarker panel, designed to detect precancerous lesions and cancer. We have submitted a Premarket Approval Application (PMA) to the FDA based on the favorable results from the pivotal CRC-PREVENT trial, in which Geneoscopy’s test demonstrated 94% sensitivity for CRC and 46% sensitivity for advanced adenomas.

The results of Genesocopy’s CRC-PREVENT trial have been published in JAMA – The Journal of the American Medical Association

The Power of RNA

Why choose RNA-based diagnostics? RNA is a dynamic and versatile molecule that shows real-time changes in the body. It is essential for protein synthesis, adjusts to disease conditions, and manages many genes in cellular processes. These changes in RNA pathways are associated with the start and progression of different cancers.

Our advanced RNA-centered approach uses the seRNA signal from epithelial cells shed in the GI tract, offering a thorough, uniform tissue sampling near a lesion. RNA-based biomarkers provide a concentrated, amplified signal across multiple transcripts in a pathway, potentially having the edge over DNA-based biomarkers. In addition, by evaluating the downstream effects of various precancerous mutations, RNA transcriptome analysis allows for accurate detection across all cancer development pathways.


The ColoRectal Cancer and PREcancerous adenoma noninvasive detectioN Test (CRC-PREVENT) trial demonstrated the efficacy of Geneoscopy’s noninvasive, stool-based, at-home diagnostic screening test to detect colorectal cancer (CRC) and advanced adenomas (AA) in average-risk individuals.

Category  Efficacy Results
Sensitivity for Detecting CRC 94%
Sensitivity for Detecting AA 46%
Specificity for No Findings on a Colonoscopy 88%
Learn More About CRC-Prevent

These sensitivity results are the highest reported for a noninvasive CRC screening test in a prospective registrational clinical study completed to date. Additionally, CRC-PREVENT is the first study to report on CRC sensitivity for individuals aged 45-49, the most recent age range added to CRC screening guidelines.

Notably, the participants in the CRC-PREVENT study represent a more diverse range of socioeconomic and racial backgrounds than typically seen in clinical trials, better reflecting the country’s demographics. This diversity helps to confirm the test’s effectiveness across various groups and promotes the crucial aim of expanding access to CRC screening for populations that have been historically underserved.

Based on the CRC-PREVENT trial results, Geneoscopy submitted a Premarket Approval Application (PMA) to the FDA and is awaiting the FDA’s decision while preparing for a commercial launch and the opportunity to provide millions of eligible adults with a new option to detect colorectal cancer.